Indeed, by combining TGFα overexpression in breast epithelial cells and the FGFR4 deficiency outside the breast, we found that ablation of FGFR4 reduced TGFα-driven breast cancer incidence, delayed breast cancer progression and improved host survival. Here, FGFR4 is linked to breast carcinoma.